- BNF:
- Not listed
- Status:
- Red
- Decision Date:
- May 2018
Comments
RED:
- NICE TA517: for treating metastatic Merkel Cell carcinoma. (Decision date - May 2018).
- NICE TA645: Avelumab with axitinib for untreated advanced renal cell carcinoma. (Decision date - Oct 2020).
- NICE TA691: for untreated metastatic
Merkel cell carcinoma. (Decision date - May 2021).
- NICE TA788: for maintenance treatment of locally advanced or metastatic
urothelial cancer after platinum-based chemotherapy. (Decision date - June 2022).
Available through the Cancer Drug Fund.
NHS England drug. To be used in line with NHSE commissioning intentions.
Red Drug Classifications
- 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
- 2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
- 3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)
- 8. NHS England commissioned – to be used in line with NHSE commissioning intentions
search again